Replies to post #207796 on Biotech Values

[DewDiligence]

ADXS—In general, I stay far and wide away from companies that have THAT many irons in the fire at such an early stage in their life.

That’s my general investing philosophy too, but I’ve made an exception with ADXS because: they are well-funded and reasonably disciplined in expense control (#msg-127726151); all of the programs are based on a shared technology platform; and there are partnerships with AMGN, AZN, and MRK to confer some validation for what ADXS is doing.

[swampboots]

I sense that a cancer remedy to contain survival rates will eventually model the HIV combination cocktail model in some form. One way this can be accelerated ( a sustained month to month remission for "ever") is for a trillion dollar Co. to buy all the most promising initiatives, overcome the sharing secrecies and go full throttle once confident they are imbued and directed with multi-strategic initiatives.
Bottom line, ADXS may be on same path on the cheap with pow-wow make nice alliances with top players. All theoretical
but I personally like the approach, my credentials are watching too many people missing this boat landing.